GlassScriptPhysician profile
Sidney A Kelt
NPI 1902855430
$19,162.61
in general payments reported to CMS, 2019-2025
36 companies · $35.61 in 2025
The $35.61 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,467 · 2020: $1,810 · 2021: $5,183 · 2022: $2,549 · 2023: $3,187 · 2024: $2,931 · 2025: $35.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,153.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $3,918.20 | 2020-2024 | Equetro |
| Otsuka America Pharmaceutical, INC. | $2,750.52 | 2019-2024 | Rexulti, Nuedexta, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,897.32 | 2019-2024 | Ingrezza |
| Lundbeck LLC | $1,009.35 | 2019-2025 | Rexulti, Brintellix |
| Janssen Pharmaceuticals, INC | $936.25 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $807.54 | 2020-2024 | Caplyta |
| Abbvie INC. | $783.98 | 2021-2024 | |
| Corium, LLC | $753.87 | 2022-2024 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $732.29 | 2019-2024 | Trintellix |
| Alkermes, INC. | $491.49 | 2021-2024 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $442.92 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $415.51 | 2021-2024 | Qelbree, Qelbree |
| Almatica Pharma LLC | $405.83 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $390.39 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $359.76 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $355.29 | 2019-2023 | Belsomra |
| Tris Pharma INC | $348.77 | 2019-2023 | Dyanavel Xr |
| Allergan, INC. | $334.83 | 2019-2020 | |
| Neos Therapeutics, LP | $322.00 | 2019-2024 | Adzenys Xr-Odt |
| Eisai INC. | $224.71 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $203.45 | 2021-2024 | Nuplazid |
| Axsome Therapeutics, INC. | $188.81 | 2022-2024 | Auvelity |
| Shire North American Group INC | $162.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $147.60 | 2023-2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $126.34 | 2019-2024 | Fanapt |
| Jazz Pharmaceuticals INC. | $121.60 | 2019-2023 | Xywav |
| Astrazeneca Pharmaceuticals LP | $112.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $87.50 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $85.87 | 2019-2023 | Jornay Pm |
| Bausch Health US, LLC | $74.37 | 2023-2024 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $68.18 | 2023-2025 | Secuado, Xelstrym |
| Harmony Biosciences LLC | $36.10 | 2021-2024 | |
| Azurity Pharmaceuticals, INC. | $23.64 | 2023 | Horizant |
| Livanova USA, INC. | $16.33 | 2020 | |
| Adlon Therapeutics L.P. | $15.40 | 2019 | |
| Aytu Biopharma, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Kelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.